Genzyme
Venture capital · Cambridge, Massachusetts, United States
Portfolio collected from the firm’s website, last checked Jun 28, 2026.Raises and exits come from each company’s own SEC and company records.
4Deep-tech portfolio0 active
4Portfolio exitsAcquired or listed
0Raises, 12 monthsLatest: Voyager Therapeutics
10Co-investorsShare a portfolio company
Portfolio · 4 companies
| Company | Sector | Status | Latest raise | Raised |
|---|---|---|---|---|
| Voyager Therapeutics | Biotech | Public | Jan 17, 2024 | $119.0M |
| Atea Pharmaceuticals | Biotech | Public | May 29, 2020 | $155.9M |
| Ra Pharmaceuticals | Biotech | Acquired | Jul 23, 2015 | $39.6M |
| Blueprint Medicines | Biotech | Acquired | Nov 20, 2014 | $73.2M |
Peer ranks
Portfolio size#108
Portfolio exits#49
Raises, 12 months#88
Co-investors#161
Co-investors
- Atlas VentureVenture capital3 shared
- RA CapitalVenture capital2 shared
- Third Rock VenturesVenture capital2 shared
- ARCH VentureVenture capital1 shared
- BiogenVenture capital1 shared
- Biotechnology Value FundVenture capital1 shared
- Deerfield Capital ManagementVenture capital1 shared
- GenentechVenture capital1 shared
- Novo HoldingsVenture capital1 shared
- Oxford Bioscience PartnersVenture capital1 shared
Sectors
- Biotech4
Portfolios are collected from investors’ own websites and matched to tracked deep-tech companies by name; duplicate listings of the same firm are merged. Exits and raises come from each company’s own record: Form D through the latest filing.